Global Escitalopram Market Research Report 2022

Publisher Name :
Date: 11-Jul-2022
No. of pages: 121
Inquire Before Buying

Due to the COVID-19 pandemic, the global Escitalopram market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Escitalopram market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Escitalopram landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Tablets accounting for % of the Escitalopram global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.

The global major manufacturers of Escitalopram include Lundbeck (DK), Amneal Pharmaceuticals (US), Forest Laboratories (US), TEVA (Israel), Mylan (US), Silarx Pharmacueticals (US), Apotex (CA), Lupin (IN) and Novartis (US), etc. In terms of revenue, the global 3 largest players have a % market share of Escitalopram in 2021.

This report focuses on Escitalopram volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Escitalopram market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Global Escitalopram Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

- Tablets

- Solution

Segment by Application

- Hospital Pharmacies

- Retail Pharmacies

- Online Pharmacies

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - China Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

By Company

- Lundbeck (DK)

- Amneal Pharmaceuticals (US)

- Forest Laboratories (US)

- TEVA (Israel)

- Mylan (US)

- Silarx Pharmacueticals (US)

- Apotex (CA)

- Lupin (IN)

- Novartis (US)

- Hikma Pharmaceuticals (UK)

- Aurobindo Pharma (IN)

- Hetero Drugs (IN)

- Accord Healthcare (IN)

- Macleods Pharmaceuticals (IN)

- Xian Janssen Pharmaceutical (CN)

- Jewim Pharmaceutical (Shandong)

- Sichuan Kelun Pharmaceutical (CN)

- Hunan Dongting Pharmaceutical (CN)

- Zhejiang Conba Pharmaceutical (CN)

- Xidian Pharmaceutical (CN)

- Zhejiang Huahai Pharmaceutical (CN)

Global Escitalopram Market Research Report 2022

Table of Contents
1 Escitalopram Market Overview
1.1 Product Overview and Scope of Escitalopram
1.2 Escitalopram Segment by Type
1.2.1 Global Escitalopram Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Tablets
1.2.3 Solution
1.3 Escitalopram Segment by Application
1.3.1 Global Escitalopram Sales Comparison by Application: (2022-2028)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Escitalopram Market Size Estimates and Forecasts
1.4.1 Global Escitalopram Revenue 2017-2028
1.4.2 Global Escitalopram Sales 2017-2028
1.4.3 Escitalopram Market Size by Region: 2017 Versus 2021 Versus 2028
2 Escitalopram Market Competition by Manufacturers
2.1 Global Escitalopram Sales Market Share by Manufacturers (2017-2022)
2.2 Global Escitalopram Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Escitalopram Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Escitalopram Manufacturing Sites, Area Served, Product Type
2.5 Escitalopram Market Competitive Situation and Trends
2.5.1 Escitalopram Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Escitalopram Players Market Share by Revenue
2.5.3 Global Escitalopram Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Escitalopram Retrospective Market Scenario by Region
3.1 Global Escitalopram Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Escitalopram Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Escitalopram Market Facts & Figures by Country
3.3.1 North America Escitalopram Sales by Country
3.3.2 North America Escitalopram Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Escitalopram Market Facts & Figures by Country
3.4.1 Europe Escitalopram Sales by Country
3.4.2 Europe Escitalopram Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Escitalopram Market Facts & Figures by Region
3.5.1 Asia Pacific Escitalopram Sales by Region
3.5.2 Asia Pacific Escitalopram Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Escitalopram Market Facts & Figures by Country
3.6.1 Latin America Escitalopram Sales by Country
3.6.2 Latin America Escitalopram Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Escitalopram Market Facts & Figures by Country
3.7.1 Middle East and Africa Escitalopram Sales by Country
3.7.2 Middle East and Africa Escitalopram Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Escitalopram Historic Market Analysis by Type
4.1 Global Escitalopram Sales Market Share by Type (2017-2022)
4.2 Global Escitalopram Revenue Market Share by Type (2017-2022)
4.3 Global Escitalopram Price by Type (2017-2022)
5 Global Escitalopram Historic Market Analysis by Application
5.1 Global Escitalopram Sales Market Share by Application (2017-2022)
5.2 Global Escitalopram Revenue Market Share by Application (2017-2022)
5.3 Global Escitalopram Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Lundbeck (DK)
6.1.1 Lundbeck (DK) Corporation Information
6.1.2 Lundbeck (DK) Description and Business Overview
6.1.3 Lundbeck (DK) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Lundbeck (DK) Escitalopram Product Portfolio
6.1.5 Lundbeck (DK) Recent Developments/Updates
6.2 Amneal Pharmaceuticals (US)
6.2.1 Amneal Pharmaceuticals (US) Corporation Information
6.2.2 Amneal Pharmaceuticals (US) Description and Business Overview
6.2.3 Amneal Pharmaceuticals (US) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Amneal Pharmaceuticals (US) Escitalopram Product Portfolio
6.2.5 Amneal Pharmaceuticals (US) Recent Developments/Updates
6.3 Forest Laboratories (US)
6.3.1 Forest Laboratories (US) Corporation Information
6.3.2 Forest Laboratories (US) Description and Business Overview
6.3.3 Forest Laboratories (US) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Forest Laboratories (US) Escitalopram Product Portfolio
6.3.5 Forest Laboratories (US) Recent Developments/Updates
6.4 TEVA (Israel)
6.4.1 TEVA (Israel) Corporation Information
6.4.2 TEVA (Israel) Description and Business Overview
6.4.3 TEVA (Israel) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.4.4 TEVA (Israel) Escitalopram Product Portfolio
6.4.5 TEVA (Israel) Recent Developments/Updates
6.5 Mylan (US)
6.5.1 Mylan (US) Corporation Information
6.5.2 Mylan (US) Description and Business Overview
6.5.3 Mylan (US) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Mylan (US) Escitalopram Product Portfolio
6.5.5 Mylan (US) Recent Developments/Updates
6.6 Silarx Pharmacueticals (US)
6.6.1 Silarx Pharmacueticals (US) Corporation Information
6.6.2 Silarx Pharmacueticals (US) Description and Business Overview
6.6.3 Silarx Pharmacueticals (US) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Silarx Pharmacueticals (US) Escitalopram Product Portfolio
6.6.5 Silarx Pharmacueticals (US) Recent Developments/Updates
6.7 Apotex (CA)
6.6.1 Apotex (CA) Corporation Information
6.6.2 Apotex (CA) Description and Business Overview
6.6.3 Apotex (CA) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Apotex (CA) Escitalopram Product Portfolio
6.7.5 Apotex (CA) Recent Developments/Updates
6.8 Lupin (IN)
6.8.1 Lupin (IN) Corporation Information
6.8.2 Lupin (IN) Description and Business Overview
6.8.3 Lupin (IN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Lupin (IN) Escitalopram Product Portfolio
6.8.5 Lupin (IN) Recent Developments/Updates
6.9 Novartis (US)
6.9.1 Novartis (US) Corporation Information
6.9.2 Novartis (US) Description and Business Overview
6.9.3 Novartis (US) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Novartis (US) Escitalopram Product Portfolio
6.9.5 Novartis (US) Recent Developments/Updates
6.10 Hikma Pharmaceuticals (UK)
6.10.1 Hikma Pharmaceuticals (UK) Corporation Information
6.10.2 Hikma Pharmaceuticals (UK) Description and Business Overview
6.10.3 Hikma Pharmaceuticals (UK) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Hikma Pharmaceuticals (UK) Escitalopram Product Portfolio
6.10.5 Hikma Pharmaceuticals (UK) Recent Developments/Updates
6.11 Aurobindo Pharma (IN)
6.11.1 Aurobindo Pharma (IN) Corporation Information
6.11.2 Aurobindo Pharma (IN) Escitalopram Description and Business Overview
6.11.3 Aurobindo Pharma (IN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Aurobindo Pharma (IN) Escitalopram Product Portfolio
6.11.5 Aurobindo Pharma (IN) Recent Developments/Updates
6.12 Hetero Drugs (IN)
6.12.1 Hetero Drugs (IN) Corporation Information
6.12.2 Hetero Drugs (IN) Escitalopram Description and Business Overview
6.12.3 Hetero Drugs (IN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Hetero Drugs (IN) Escitalopram Product Portfolio
6.12.5 Hetero Drugs (IN) Recent Developments/Updates
6.13 Accord Healthcare (IN)
6.13.1 Accord Healthcare (IN) Corporation Information
6.13.2 Accord Healthcare (IN) Escitalopram Description and Business Overview
6.13.3 Accord Healthcare (IN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Accord Healthcare (IN) Escitalopram Product Portfolio
6.13.5 Accord Healthcare (IN) Recent Developments/Updates
6.14 Macleods Pharmaceuticals (IN)
6.14.1 Macleods Pharmaceuticals (IN) Corporation Information
6.14.2 Macleods Pharmaceuticals (IN) Escitalopram Description and Business Overview
6.14.3 Macleods Pharmaceuticals (IN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Macleods Pharmaceuticals (IN) Escitalopram Product Portfolio
6.14.5 Macleods Pharmaceuticals (IN) Recent Developments/Updates
6.15 Xian Janssen Pharmaceutical (CN)
6.15.1 Xian Janssen Pharmaceutical (CN) Corporation Information
6.15.2 Xian Janssen Pharmaceutical (CN) Escitalopram Description and Business Overview
6.15.3 Xian Janssen Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Xian Janssen Pharmaceutical (CN) Escitalopram Product Portfolio
6.15.5 Xian Janssen Pharmaceutical (CN) Recent Developments/Updates
6.16 Jewim Pharmaceutical (Shandong)
6.16.1 Jewim Pharmaceutical (Shandong) Corporation Information
6.16.2 Jewim Pharmaceutical (Shandong) Escitalopram Description and Business Overview
6.16.3 Jewim Pharmaceutical (Shandong) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Jewim Pharmaceutical (Shandong) Escitalopram Product Portfolio
6.16.5 Jewim Pharmaceutical (Shandong) Recent Developments/Updates
6.17 Sichuan Kelun Pharmaceutical (CN)
6.17.1 Sichuan Kelun Pharmaceutical (CN) Corporation Information
6.17.2 Sichuan Kelun Pharmaceutical (CN) Escitalopram Description and Business Overview
6.17.3 Sichuan Kelun Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Sichuan Kelun Pharmaceutical (CN) Escitalopram Product Portfolio
6.17.5 Sichuan Kelun Pharmaceutical (CN) Recent Developments/Updates
6.18 Hunan Dongting Pharmaceutical (CN)
6.18.1 Hunan Dongting Pharmaceutical (CN) Corporation Information
6.18.2 Hunan Dongting Pharmaceutical (CN) Escitalopram Description and Business Overview
6.18.3 Hunan Dongting Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Hunan Dongting Pharmaceutical (CN) Escitalopram Product Portfolio
6.18.5 Hunan Dongting Pharmaceutical (CN) Recent Developments/Updates
6.19 Zhejiang Conba Pharmaceutical (CN)
6.19.1 Zhejiang Conba Pharmaceutical (CN) Corporation Information
6.19.2 Zhejiang Conba Pharmaceutical (CN) Escitalopram Description and Business Overview
6.19.3 Zhejiang Conba Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Zhejiang Conba Pharmaceutical (CN) Escitalopram Product Portfolio
6.19.5 Zhejiang Conba Pharmaceutical (CN) Recent Developments/Updates
6.20 Xidian Pharmaceutical (CN)
6.20.1 Xidian Pharmaceutical (CN) Corporation Information
6.20.2 Xidian Pharmaceutical (CN) Escitalopram Description and Business Overview
6.20.3 Xidian Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Xidian Pharmaceutical (CN) Escitalopram Product Portfolio
6.20.5 Xidian Pharmaceutical (CN) Recent Developments/Updates
6.21 Zhejiang Huahai Pharmaceutical (CN)
6.21.1 Zhejiang Huahai Pharmaceutical (CN) Corporation Information
6.21.2 Zhejiang Huahai Pharmaceutical (CN) Escitalopram Description and Business Overview
6.21.3 Zhejiang Huahai Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Zhejiang Huahai Pharmaceutical (CN) Escitalopram Product Portfolio
6.21.5 Zhejiang Huahai Pharmaceutical (CN) Recent Developments/Updates
7 Escitalopram Manufacturing Cost Analysis
7.1 Escitalopram Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Escitalopram
7.4 Escitalopram Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Escitalopram Distributors List
8.3 Escitalopram Customers
9 Escitalopram Market Dynamics
9.1 Escitalopram Industry Trends
9.2 Escitalopram Market Drivers
9.3 Escitalopram Market Challenges
9.4 Escitalopram Market Restraints
10 Global Market Forecast
10.1 Escitalopram Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Escitalopram by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Escitalopram by Type (2023-2028)
10.2 Escitalopram Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Escitalopram by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Escitalopram by Application (2023-2028)
10.3 Escitalopram Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Escitalopram by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Escitalopram by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Escitalopram Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Escitalopram Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Escitalopram Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Escitalopram Market Competitive Situation by Manufacturers in 2021
Table 5. Global Escitalopram Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Escitalopram Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Escitalopram Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Escitalopram Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Escitalopram Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Escitalopram Manufacturing Sites and Area Served
Table 11. Manufacturers Escitalopram Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Escitalopram by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Escitalopram as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Escitalopram Sales by Region (2017-2022) & (K Units)
Table 16. Global Escitalopram Sales Market Share by Region (2017-2022)
Table 17. Global Escitalopram Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Escitalopram Revenue Market Share by Region (2017-2022)
Table 19. North America Escitalopram Sales by Country (2017-2022) & (K Units)
Table 20. North America Escitalopram Sales Market Share by Country (2017-2022)
Table 21. North America Escitalopram Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Escitalopram Revenue Market Share by Country (2017-2022)
Table 23. Europe Escitalopram Sales by Country (2017-2022) & (K Units)
Table 24. Europe Escitalopram Sales Market Share by Country (2017-2022)
Table 25. Europe Escitalopram Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Escitalopram Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Escitalopram Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Escitalopram Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Escitalopram Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Escitalopram Revenue Market Share by Region (2017-2022)
Table 31. Latin America Escitalopram Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Escitalopram Sales Market Share by Country (2017-2022)
Table 33. Latin America Escitalopram Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Escitalopram Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Escitalopram Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Escitalopram Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Escitalopram Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Escitalopram Revenue Market Share by Country (2017-2022)
Table 39. Global Escitalopram Sales by Type (2017-2022) & (K Units)
Table 40. Global Escitalopram Sales Market Share by Type (2017-2022)
Table 41. Global Escitalopram Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Escitalopram Revenue Share by Type (2017-2022)
Table 43. Global Escitalopram Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Escitalopram Sales (K Units) by Application (2017-2022)
Table 45. Global Escitalopram Sales Market Share by Application (2017-2022)
Table 46. Global Escitalopram Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Escitalopram Revenue Share by Application (2017-2022)
Table 48. Global Escitalopram Price by Application (2017-2022) & (US$/Unit)
Table 49. Lundbeck (DK) Corporation Information
Table 50. Lundbeck (DK) Description and Business Overview
Table 51. Lundbeck (DK) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. Lundbeck (DK) Escitalopram Product
Table 53. Lundbeck (DK) Recent Developments/Updates
Table 54. Amneal Pharmaceuticals (US) Corporation Information
Table 55. Amneal Pharmaceuticals (US) Description and Business Overview
Table 56. Amneal Pharmaceuticals (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Amneal Pharmaceuticals (US) Escitalopram Product
Table 58. Amneal Pharmaceuticals (US) Recent Developments/Updates
Table 59. Forest Laboratories (US) Corporation Information
Table 60. Forest Laboratories (US) Description and Business Overview
Table 61. Forest Laboratories (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Forest Laboratories (US) Escitalopram Product
Table 63. Forest Laboratories (US) Recent Developments/Updates
Table 64. TEVA (Israel) Corporation Information
Table 65. TEVA (Israel) Description and Business Overview
Table 66. TEVA (Israel) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. TEVA (Israel) Escitalopram Product
Table 68. TEVA (Israel) Recent Developments/Updates
Table 69. Mylan (US) Corporation Information
Table 70. Mylan (US) Description and Business Overview
Table 71. Mylan (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Mylan (US) Escitalopram Product
Table 73. Mylan (US) Recent Developments/Updates
Table 74. Silarx Pharmacueticals (US) Corporation Information
Table 75. Silarx Pharmacueticals (US) Description and Business Overview
Table 76. Silarx Pharmacueticals (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Silarx Pharmacueticals (US) Escitalopram Product
Table 78. Silarx Pharmacueticals (US) Recent Developments/Updates
Table 79. Apotex (CA) Corporation Information
Table 80. Apotex (CA) Description and Business Overview
Table 81. Apotex (CA) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Apotex (CA) Escitalopram Product
Table 83. Apotex (CA) Recent Developments/Updates
Table 84. Lupin (IN) Corporation Information
Table 85. Lupin (IN) Description and Business Overview
Table 86. Lupin (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Lupin (IN) Escitalopram Product
Table 88. Lupin (IN) Recent Developments/Updates
Table 89. Novartis (US) Corporation Information
Table 90. Novartis (US) Description and Business Overview
Table 91. Novartis (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Novartis (US) Escitalopram Product
Table 93. Novartis (US) Recent Developments/Updates
Table 94. Hikma Pharmaceuticals (UK) Corporation Information
Table 95. Hikma Pharmaceuticals (UK) Description and Business Overview
Table 96. Hikma Pharmaceuticals (UK) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Hikma Pharmaceuticals (UK) Escitalopram Product
Table 98. Hikma Pharmaceuticals (UK) Recent Developments/Updates
Table 99. Aurobindo Pharma (IN) Corporation Information
Table 100. Aurobindo Pharma (IN) Description and Business Overview
Table 101. Aurobindo Pharma (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Aurobindo Pharma (IN) Escitalopram Product
Table 103. Aurobindo Pharma (IN) Recent Developments/Updates
Table 104. Hetero Drugs (IN) Corporation Information
Table 105. Hetero Drugs (IN) Description and Business Overview
Table 106. Hetero Drugs (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Hetero Drugs (IN) Escitalopram Product
Table 108. Hetero Drugs (IN) Recent Developments/Updates
Table 109. Accord Healthcare (IN) Corporation Information
Table 110. Accord Healthcare (IN) Description and Business Overview
Table 111. Accord Healthcare (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Accord Healthcare (IN) Escitalopram Product
Table 113. Accord Healthcare (IN) Recent Developments/Updates
Table 114. Macleods Pharmaceuticals (IN) Corporation Information
Table 115. Macleods Pharmaceuticals (IN) Description and Business Overview
Table 116. Macleods Pharmaceuticals (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 117. Macleods Pharmaceuticals (IN) Escitalopram Product
Table 118. Macleods Pharmaceuticals (IN) Recent Developments/Updates
Table 119. Xian Janssen Pharmaceutical (CN) Corporation Information
Table 120. Xian Janssen Pharmaceutical (CN) Description and Business Overview
Table 121. Xian Janssen Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 122. Xian Janssen Pharmaceutical (CN) Escitalopram Product
Table 123. Xian Janssen Pharmaceutical (CN) Recent Developments/Updates
Table 124. Jewim Pharmaceutical (Shandong) Corporation Information
Table 125. Jewim Pharmaceutical (Shandong) Description and Business Overview
Table 126. Jewim Pharmaceutical (Shandong) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 127. Jewim Pharmaceutical (Shandong) Escitalopram Product
Table 128. Jewim Pharmaceutical (Shandong) Recent Developments/Updates
Table 129. Sichuan Kelun Pharmaceutical (CN) Corporation Information
Table 130. Sichuan Kelun Pharmaceutical (CN) Description and Business Overview
Table 131. Sichuan Kelun Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 132. Sichuan Kelun Pharmaceutical (CN) Escitalopram Product
Table 133. Sichuan Kelun Pharmaceutical (CN) Recent Developments/Updates
Table 134. Hunan Dongting Pharmaceutical (CN) Corporation Information
Table 135. Hunan Dongting Pharmaceutical (CN) Description and Business Overview
Table 136. Hunan Dongting Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 137. Hunan Dongting Pharmaceutical (CN) Escitalopram Product
Table 138. Hunan Dongting Pharmaceutical (CN) Recent Developments/Updates
Table 139. Zhejiang Conba Pharmaceutical (CN) Corporation Information
Table 140. Zhejiang Conba Pharmaceutical (CN) Description and Business Overview
Table 141. Zhejiang Conba Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 142. Zhejiang Conba Pharmaceutical (CN) Escitalopram Product
Table 143. Zhejiang Conba Pharmaceutical (CN) Recent Developments/Updates
Table 144. Xidian Pharmaceutical (CN) Corporation Information
Table 145. Xidian Pharmaceutical (CN) Description and Business Overview
Table 146. Xidian Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 147. Xidian Pharmaceutical (CN) Escitalopram Product
Table 148. Xidian Pharmaceutical (CN) Recent Developments/Updates
Table 149. Zhejiang Huahai Pharmaceutical (CN) Corporation Information
Table 150. Zhejiang Huahai Pharmaceutical (CN) Description and Business Overview
Table 151. Zhejiang Huahai Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 152. Zhejiang Huahai Pharmaceutical (CN) Escitalopram Product
Table 153. Zhejiang Huahai Pharmaceutical (CN) Recent Developments/Updates
Table 154. Production Base and Market Concentration Rate of Raw Material
Table 155. Key Suppliers of Raw Materials
Table 156. Escitalopram Distributors List
Table 157. Escitalopram Customers List
Table 158. Escitalopram Market Trends
Table 159. Escitalopram Market Drivers
Table 160. Escitalopram Market Challenges
Table 161. Escitalopram Market Restraints
Table 162. Global Escitalopram Sales Forecast by Type (2023-2028) & (K Units)
Table 163. Global Escitalopram Sales Market Share Forecast by Type (2023-2028)
Table 164. Global Escitalopram Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 165. Global Escitalopram Revenue Market Share Forecast by Type (2023-2028)
Table 166. Global Escitalopram Sales Forecast by Application (2023-2028) & (K Units)
Table 167. Global Escitalopram Sales Market Share Forecast by Application (2023-2028)
Table 168. Global Escitalopram Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 169. Global Escitalopram Revenue Market Share Forecast by Application (2023-2028)
Table 170. Global Escitalopram Sales Forecast by Region (2023-2028) & (K Units)
Table 171. Global Escitalopram Sales Market Share Forecast by Region (2023-2028)
Table 172. Global Escitalopram Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 173. Global Escitalopram Revenue Market Share Forecast by Region (2023-2028)
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Escitalopram
Figure 2. Global Escitalopram Market Share by Type in 2021 & 2028
Figure 3. Tablets Product Picture
Figure 4. Solution Product Picture
Figure 5. Global Escitalopram Market Share by Application in 2021 & 2028
Figure 6. Hospital Pharmacies
Figure 7. Retail Pharmacies
Figure 8. Online Pharmacies
Figure 9. Global Escitalopram Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 10. Global Escitalopram Market Size (2017-2028) & (US$ Million)
Figure 11. Global Escitalopram Sales (2017-2028) & (K Units)
Figure 12. Escitalopram Sales Share by Manufacturers in 2021
Figure 13. Global Escitalopram Revenue Share by Manufacturers in 2021
Figure 14. The Global 5 and 10 Largest Escitalopram Players: Market Share by Revenue in 2021
Figure 15. Escitalopram Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 16. Global Escitalopram Sales Market Share by Region (2017-2022)
Figure 17. Global Escitalopram Sales Market Share by Region in 2021
Figure 18. Global Escitalopram Revenue Market Share by Region (2017-2022)
Figure 19. Global Escitalopram Revenue Market Share by Region in 2021
Figure 20. U.S. Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Canada Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Germany Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. France Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. U.K. Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Italy Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Russia Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. China Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Japan Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. South Korea Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. India Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Australia Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. China Taiwan Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Indonesia Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Thailand Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Malaysia Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Mexico Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Brazil Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Argentina Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Turkey Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Saudi Arabia Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. UAE Escitalopram Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Sales Market Share of Escitalopram by Type (2017-2022)
Figure 43. Manufacturing Cost Structure of Escitalopram
Figure 44. Manufacturing Process Analysis of Escitalopram
Figure 45. Escitalopram Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
  • Global Divalproex Sodium Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 81
    Divalproex Sodium is used to treat certain types of seizures (epilepsy). This medicine is an anticonvulsant that works in The brain tissue to stop seizures. Divalproex Sodium is also used to treat The manic phase of bipolar disorder (manic-depressive illness), and helps prevent migraine headaches. This medicine is available only with your doctor's prescription. The global Divalproex Sodium market was valued at US$ 2188.5 million in 2023 and is anticipated to reach US$ 33......
  • Global Divalproex Sodium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 90
    According to our LPI (LP Information) latest study, the global Divalproex Sodium market size was valued at US$ 2140.9 million in 2023. With growing demand in downstream market, the Divalproex Sodium is forecast to a readjusted size of US$ 3312 million by 2030 with a CAGR of 6.4% during review period. The research report highlights the growth potential of the global Divalproex Sodium market. Divalproex Sodium are expected to show stable growth in the future market. However, product differ......
  • Global Quetiapine Fumarate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Quetiapine Fumarate market size was valued at US$ 156.2 million in 2023. With growing demand in downstream market, the Quetiapine Fumarate is forecast to a readjusted size of US$ 132.9 million by 2030 with a CAGR of -2.3% during review period. The research report highlights the growth potential of the global Quetiapine Fumarate market. Quetiapine Fumarate are expected to show stable growth in the future market. However, produ......
  • Global Clozapine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 114
    According to our LPI (LP Information) latest study, the global Clozapine market size was valued at US$ 341.4 million in 2023. With growing demand in downstream market, the Clozapine is forecast to a readjusted size of US$ 463.4 million by 2030 with a CAGR of 4.5% during review period. The research report highlights the growth potential of the global Clozapine market. Clozapine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and s......
  • Global Trazodone Hydrochloride (API) Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 92
    According to our LPI (LP Information) latest study, the global Trazodone Hydrochloride (API) market size was valued at US$ million in 2023. With growing demand in downstream market, the Trazodone Hydrochloride (API) is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Trazodone Hydrochloride (API) market. Trazodone Hydrochloride (API) are expected to show stable growth in the future......
  • Global Trazodone Hydrochloride (API) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 93
    According to our (Global Info Research) latest study, the global Trazodone Hydrochloride (API) market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period. Trazodone, a phenylpiperazine-triazolopyridine antidepressant, was originally discovered and developed in Italy in the 1970s by Angelini research laboratories. Trazodone is used to treat depression and to treat the combination of symptoms of anxiety an......
  • Global Divalproex Sodium Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 91
    According to our (Global Info Research) latest study, the global Divalproex Sodium market size was valued at USD 2251.9 million in 2023 and is forecast to a readjusted size of USD 3371.1 million by 2030 with a CAGR of 5.9% during review period. Divalproex Sodium is used to treat certain types of seizures (epilepsy). This medicine is an anticonvulsant that works in the brain tissue to stop seizures. Divalproex Sodium is also used to treat the manic phase of bipolar disorder (manic-d......
  • Global Risperidone Market Research Report 2023
    Published: 28-Dec-2023        Price: US 2900 Onwards        Pages: 93
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Risperidone market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Janssen (Johnson & Johnson) - Ajanta Pharma - Amneal Pharmaceuticals - Aurobindo Pharma - Hikma - Sandoz - Lannett - Tris Pharma - Ap......
  • Global Schizophrenia Therapeutics Market Status and Outlook 2023-2028
    Published: 27-Dec-2023        Price: US 3160 Onwards        Pages: 101
    Schizophrenia is usually treated with an individually tailored combination of talking therapy and medicine. Most people with schizophrenia are treated by community mental health teams (CMHTs). The goal of the CMHT is to provide day-to-day support and treatment while ensuring you have as much independence as possible. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market va......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs